Literature DB >> 22571878

Asialoglycoprotein receptor (ASGPR) as target autoantigen in liver autoimmunity: lost and found.

Eirini I Rigopoulou1, Dirk Roggenbuck, Daniel S Smyk, Christos Liaskos, Maria G Mytilinaiou, Eugen Feist, Karsten Conrad, Dimitrios P Bogdanos.   

Abstract

Asialoglycoprotein receptor (ASGPR) has attracted the attention of liver immunologists for many years. This liver-specific lectin was found to be a major B and T cell autoantigenic target in patients with autoimmune liver diseases, and in particular in autoimmune hepatitis (AIH). This review discusses the biological significance of ASGPR and its relevance to the pathogenesis of autoimmune and virus-triggered liver diseases. We also discuss emerging data on the diagnostic and clinical relevance of anti-ASGPR antibodies in light of recent reports based on commercially available anti-ASGPR enzyme-linked immunosorbent assays. Finally, we critically revisit the data reporting on disease-specific cellular immune responses against ASGPR and their relevance in relation to the pathogenesis of AIH.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22571878     DOI: 10.1016/j.autrev.2012.04.005

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  27 in total

Review 1.  Juvenile autoimmune hepatitis: Spectrum of the disease.

Authors:  Giuseppe Maggiore; Silvia Nastasio; Marco Sciveres
Journal:  World J Hepatol       Date:  2014-07-27

Review 2.  Transitioning from Idiopathic to Explainable Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

Review 3.  The Role of Autoantibody Testing in Modern Personalized Medicine.

Authors:  Cristiane Kayser; Lívia Almeida Dutra; Edgard Torres Dos Reis-Neto; Charlles Heldan de Moura Castro; Marvin J Fritzler; Luis Eduardo C Andrade
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-04       Impact factor: 10.817

4.  Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What's New?

Authors:  Daniel S Smyk; Eirini I Rigopoulou; Dimitrios P Bogdanos
Journal:  Curr Infect Dis Rep       Date:  2013-02       Impact factor: 3.725

Review 5.  Extracellular vesicles in obesity and its associated inflammation.

Authors:  Vijay Kumar; Sonia Kiran; Santosh Kumar; Udai P Singh
Journal:  Int Rev Immunol       Date:  2021-08-23       Impact factor: 5.311

6.  Enhanced Binding and Reduced Immunogenicity of Glycoconjugates Prepared via Solid-State Photoactivation of Aliphatic Diazirine Carbohydrates.

Authors:  Molly D Congdon; Jeffrey C Gildersleeve
Journal:  Bioconjug Chem       Date:  2020-12-16       Impact factor: 6.069

7.  Promising galactose-decorated biodegradable poloxamer 188-PLGA diblock copolymer nanoparticles of resibufogenin for enhancing liver cancer therapy.

Authors:  Hao Dong; Li Tian; Meng Gao; Hong Xu; Chenghong Zhang; Li Lv; Jianbin Zhang; Changyuan Wang; Yan Tian; Xiaochi Ma
Journal:  Drug Deliv       Date:  2017-11       Impact factor: 6.419

8.  The Novel Crohn's Disease Marker Anti-GP2 Antibody Is Associated with Ileocolonic Location of Disease.

Authors:  Valentina Somma; Hani Ababneh; Ahmad Ababneh; Simona Gatti; Vittorio Romagnoli; Emanuele Bendia; Karsten Conrad; Dimitrios P Bogdanos; Dirk Roggenbuck; Gino Ciarrocchi
Journal:  Gastroenterol Res Pract       Date:  2013-05-15       Impact factor: 2.260

9.  Tuberculosis is not a risk factor for primary biliary cirrhosis: a review of the literature.

Authors:  Daniel S Smyk; Dimitrios P Bogdanos; Albert Pares; Christos Liaskos; Charalambos Billinis; Andrew K Burroughs; Eirini I Rigopoulou
Journal:  Tuberc Res Treat       Date:  2012-10-30

10.  Preliminary Study on Hepatocyte-Targeted Phosphorus-31 MRS Using ATP-Loaded Galactosylated Chitosan Oligosaccharide Nanoparticles.

Authors:  Ri-Sheng Yu; Xiu-Liang Zhu; Jian-Zhong Sun; Dan Shi; Ying Chen; Zhi-Kang Wang; Ke-Zhong Tang; Yong-Zhong Du
Journal:  Gastroenterol Res Pract       Date:  2013-12-02       Impact factor: 2.260

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.